文献速递头颈外科咽喉与嗓音

新辅助帕博利珠单抗完全病理缓解:术中PET/CT病例报告与探索性分析

Complete Pathologic Response to Neoadjuvant Pembrolizumab Captured on Intraoperative PET/CT: A Case Report and Exploratory Analysis.
PubMed 文献 · Head Neck · 2026-09-03

本文报告一例55岁cT3N2c声门上型鳞状细胞癌患者,接受2周期新辅助帕博利珠单抗后行喉切除术,术中micro-PET/CT显示肿瘤区与气管造口 site 摄取相似,最终病理为完全病理缓解(pCR)。提示术中micro-PET/CT在评估新辅助免疫治疗反应方面具有潜在价值。

要点

  • 新辅助帕博利珠单抗后可达pCR,但影像学残留摄取可能误导判断。
  • 术中micro-PET/CT可实时评估肿瘤及切缘代谢活性。
  • 原发灶与气管造口部位SUVmax相近,提示需结合病理确认pCR。

核心结论

  • 本例pCR患者术中micro-PET/CT显示原发肿瘤部位与气管造口部位代谢亲和力相似,提示该新型影像方法在新辅助免疫治疗患者中具有潜在应用价值。

研究设计与样本

  • 病例报告与探索性分析:一例55岁男性cT3N2c声门上型鳞状细胞癌患者,接受2周期新辅助帕博利珠单抗后行喉切除术,标本行术中micro-PET/CT成像。

主要发现

  • 最终病理证实为完全病理缓解(pCR)。
  • 治疗前全身PET/CT示肿瘤SUVmax为21.8,气管造口部位SUVmax为10.7(约50%)。
  • 术中micro-PET/CT示肿瘤区域残留摄取SUVmax为16.1,气管造口部位SUVmax为16.9。

关键数值与推荐

  • 联合阳性评分(CPS)为5。
  • 治疗前肿瘤SUVmax 21.8,气管造口部位SUVmax 10.7(约50%)。
  • 术中micro-PET/CT肿瘤区域SUVmax 16.1,气管造口部位SUVmax 16.9。

临床怎么用

  • 对于接受新辅助免疫治疗的头颈癌患者,术中micro-PET/CT可能辅助评估肿瘤及切缘代谢活性,但需警惕残留摄取与pCR不一致的情况,最终仍需病理确认。

局限性

  • 单个病例报告,结论需更大样本验证;术中micro-PET/CT的标准化与可及性未讨论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant immunotherapy is an emerging treatment for patients with head and neck cancer. Given the heterogeneity of response, novel methods of intraoperative tumor and margin assessment warrant investigation. METHODS: A 55-year-old male presented with a cT3N2c supraglottic squamous cell carcinoma with a combined positive score of 5. The patient received 2 cycles of neoadjuvant pembrolizumab prior to laryngectomy. The specimen underwent intraoperative micro-positron emission tomography/computed tomography (micro-PET/CT) imaging. RESULTS: Final pathology demonstrated a pathologic complete response (pCR). On pre-treatment whole body PET/CT, maximum standardized uptake value (SUVmax) was 21.8 in the tumor and 10.7 (~50%) at the tracheostomy site. Intraoperative micro-PET/CT showed residual uptake in the tumor region (SUVmax 16.1) and tracheostomy site (SUVmax 16.9). CONCLUSION: In this case report of pCR, intraoperative micro-PET/CT demonstrated similar avidity at the primary tumor site compared to the tracheostomy site, highlighting the potential utility of this novel imaging approach in patients receiving neoadjuvant immunotherapy.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Austerlitz J, Radevic A, McAdoo A, et al. Complete Pathologic Response to Neoadjuvant Pembrolizumab Captured on Intraoperative PET/CT: A Case Report and Exploratory Analysis. Head Neck. 2026. PMID: 42693001. doi:10.1002/hed.70459

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。